Daratumumab in first-line is cost-effective in transplant-eligible newly diagnosed myeloma patients.

Published 2022 View Full Article

  1. Home
  2. Publications
  3. Publication Search
  4. Publication Details
Title
Daratumumab in first-line is cost-effective in transplant-eligible newly diagnosed myeloma patients.
Authors
Keywords
-
Journal
BLOOD
Volume -, Issue -, Pages -
Publisher
American Society of Hematology
Online
2022-05-18
DOI
10.1182/blood.2021015220

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Reprint

Contact the author

Find Funding. Review Successful Grants.

Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.

Explore

Discover Peeref hubs

Discuss science. Find collaborators. Network.

Join a conversation
Webinars Posters Questions Hubs Funding Journals Articles Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.